First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies.
about
Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysisAntidepressants for depression during pregnancyThe Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Antidepressants, anxiolytics, and hypnotics in pregnancy and lactationCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersAntidepressant use in pregnancy: a critical review focused on risks and controversiesMethodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data.Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports.Antidepressant use in pregnancy and the risk of cardiac defectsSelective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects.Can nonrandomized studies on the safety of antidepressants during pregnancy convincingly beat confounding, chance, and prior beliefs?Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence.Antidepressant use in pregnant and postpartum womenGenetic basis of congenital cardiovascular malformationsPharmacological treatment of unipolar depression during pregnancy and breast-feeding--a clinical overview.Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort studyAssociation of antenatal depression with adverse consequences for the mother and newborn in rural Ghana: findings from the DON population-based cohort study.Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?Women's perception of risks of adverse fetal pregnancy outcomes: a large-scale multinational survey.Use of prescription medicines in Australian women of child-bearing age.Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort studyThe effect of telephone-based interpersonal psychotherapy for the treatment of postpartum depression: study protocol for a randomized controlled trial.Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort StudiesThe risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.Selective Serotonin Reuptake Inhibitor Use during Pregnancy and the Risk of Autism Spectrum Disorders: A ReviewCanadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly.The effect of regulatory advisories on maternal antidepressant prescribing, 1995-2007: an interrupted time series study of 228,876 pregnancies.Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort.Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update.Antidepressant use in pregnancy.Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations.Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence.The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review.Antidepressant use in pregnancy: knowledge transfer and translation of research findings.Preventing birth defects: The value of the NBDPS case-control approach.Depression During Pregnancy and Postpartum.Depression and Anxiety During Pregnancy: Evaluating the Literature in Support of Clinical Risk-Benefit Decision-Making.Selective serotonin reuptake inhibitors and risk of major congenital anomalies for pregnancies in Japan: A nationwide birth cohort study of the Japan Environment and Children's Study.
P2860
Q21198704-386B924F-B95C-423D-8156-1A81ED44939BQ24200798-F56C8860-7216-46F6-9E2A-1EE6723653B8Q26741187-C4AE9934-AED8-4D0B-ABA5-D919B6F9CC85Q26795384-3F8DF0E3-2DC4-4FCD-8919-0AC709622EA3Q27009995-69646CB3-49C3-4F1E-8CB6-9FBD77FE6A94Q28281407-C793413E-C60D-4713-AF91-FD7B61CDB075Q30966054-20457511-492A-40E4-862C-E4C009DF4C6BQ30979346-7036113A-3FCC-420A-BCBF-543BB3F42541Q33775616-0085E9E7-24DC-4F6E-BD2C-3106214F1BDEQ33801507-348DFB99-B9C8-4658-AC20-B3E3D1C84AE7Q34049650-A9B10248-66F3-4C5E-8D83-F642AD1C7FF1Q34062619-0C8015D3-7374-443E-849A-986E8331E7EAQ34068023-C4320C79-00DB-4441-B3CC-AA5CC8E70BA1Q34125381-604B226B-FD5E-4CB4-BD15-A2EF44CBB0C3Q34250131-5DAD3BF6-462C-4E13-8610-82E48FA2359EQ34702282-D7EB58AF-B647-41E8-9912-752C4C4D14DEQ34790473-F530F6A0-8D62-4A4D-AA2B-240AE478EFD9Q35541040-598F148C-2D40-472D-918F-9EEBFBF11F23Q35608913-2CC6BEF0-0281-41EA-B2CA-FDDF5D50C1CAQ35691721-C94621D1-1D04-4C06-95F4-A354A9F635B5Q35862755-45E8252B-E67B-43AA-B9DC-E962B3BCE79DQ36045075-DA09AB89-D9F6-4382-BAF2-455297994A6BQ36116351-CC101BF8-E316-49A3-B504-27CBA04E9C61Q36141324-9571F7EE-AB07-4DF5-BB90-2999A7DD0684Q36706789-988226AE-CD12-4BD0-9FE1-330A8A8F9264Q37032700-A0FE2D7A-CA4E-4183-A75E-8148501396C4Q37197207-668B3A8E-301C-48C6-91D4-65562B273E4DQ37606641-6765D1A3-E42D-45BF-B154-661FE11E9678Q37612128-C6781107-A427-4FBA-8C34-1049F8F8026CQ37777007-F615899D-B679-403A-9CEB-9BFDC242A8BAQ37872295-D1D63F2C-0753-4B92-AE38-AD2913B7C2C6Q37943435-D92CEAF3-EAB1-47F4-99DF-DE1D0704B4DAQ38114044-85955BDD-1D39-45A3-87DB-EFA2EBEFC1ABQ38305749-A04621BB-D512-4EDB-9833-D1FEC773E299Q38382317-E5AEDF9B-66D1-4604-B355-81838B28E731Q38391359-B2615FD4-883C-41EC-9A18-D24BA644DB60Q38546831-D6CFE9B1-876B-4027-9E82-924809EE0282Q38734781-002F56F9-EE69-49A0-A08D-29DBF648F581Q38811512-102A55CC-AF96-4F90-8100-48BFA0366572Q39160045-E51CF0DA-AE63-4EB8-A084-322A8BD7F717
P2860
First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
First trimester paroxetine use ...... is of epidemiological studies.
@en
First trimester paroxetine use ...... is of epidemiological studies.
@nl
type
label
First trimester paroxetine use ...... is of epidemiological studies.
@en
First trimester paroxetine use ...... is of epidemiological studies.
@nl
prefLabel
First trimester paroxetine use ...... is of epidemiological studies.
@en
First trimester paroxetine use ...... is of epidemiological studies.
@nl
P2093
P2860
P356
P1476
First trimester paroxetine use ...... is of epidemiological studies.
@en
P2093
Andrew F Olshan
Charles Poole
Keele E Wurst
Sara A Ephross
P2860
P304
P356
10.1002/BDRA.20627
P577
2010-03-01T00:00:00Z